Many animal model studies, including recent data for an ALS/ fronto-temporal degeneration (FTD) mouse (White et al., 2019), suggest that removing Sarm1 and blocking programmed axon degeneration is a promising therapeutic strategy for axonopathies (Coleman and Höke, 2020; Conforti et al., 2014; DiAntonio, 2019; Loring and Thompson, 2020). The gene discussed is SARM1; the disease is amyotrophic lateral sclerosis.